CN114269715A - 作为氨基酸转运抑制剂的二苄基胺 - Google Patents

作为氨基酸转运抑制剂的二苄基胺 Download PDF

Info

Publication number
CN114269715A
CN114269715A CN202080056932.1A CN202080056932A CN114269715A CN 114269715 A CN114269715 A CN 114269715A CN 202080056932 A CN202080056932 A CN 202080056932A CN 114269715 A CN114269715 A CN 114269715A
Authority
CN
China
Prior art keywords
amino
compound
benzyl
cancer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080056932.1A
Other languages
English (en)
Chinese (zh)
Inventor
H·C·曼宁
M·舒尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of CN114269715A publication Critical patent/CN114269715A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202080056932.1A 2019-06-12 2020-06-12 作为氨基酸转运抑制剂的二苄基胺 Pending CN114269715A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962860571P 2019-06-12 2019-06-12
US62/860,571 2019-06-12
PCT/US2020/037527 WO2020252336A1 (en) 2019-06-12 2020-06-12 Dibenzylamines as amino acid transport inhibitors

Publications (1)

Publication Number Publication Date
CN114269715A true CN114269715A (zh) 2022-04-01

Family

ID=71409525

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080056932.1A Pending CN114269715A (zh) 2019-06-12 2020-06-12 作为氨基酸转运抑制剂的二苄基胺

Country Status (7)

Country Link
US (1) US20220265590A1 (https=)
EP (1) EP3983377A1 (https=)
JP (1) JP2022536728A (https=)
CN (1) CN114269715A (https=)
AU (1) AU2020291936A1 (https=)
CA (1) CA3141414A1 (https=)
WO (1) WO2020252336A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116410152A (zh) * 2023-04-13 2023-07-11 江苏征瑞医药科技有限公司 一种抑制asct2的小分子化合物、其衍生物及其应用
CN117466761A (zh) * 2022-07-21 2024-01-30 中国药科大学 谷氨酰胺转运抑制剂、药物组合物和应用
CN117550997A (zh) * 2023-11-09 2024-02-13 中国药科大学 一种lat1抑制剂及其制法和应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
EP3849535A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
EP3849537B1 (en) 2018-09-10 2024-10-23 Mirati Therapeutics, Inc. Combination therapies
MX2021002804A (es) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
JP2023553492A (ja) 2020-12-15 2023-12-21 ミラティ セラピューティクス， インコーポレイテッド アザキナゾリン汎ＫＲａｓ阻害剤
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
US20240174658A1 (en) * 2021-03-01 2024-05-30 Vanderbilt University Heteroaromatic Inhibitors of Cancer Metabolism
KR102635329B1 (ko) * 2021-07-21 2024-02-13 경북대학교 산학협력단 혈관평활근세포의 증식 또는 이동 억제 효과를 갖는 화합물을 유효성분으로 포함하는 혈관평활근세포 이상 증식성 질환의 예방 또는 치료용 약학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018107173A1 (en) * 2016-12-09 2018-06-14 Vanderbilt University Glutamine transport inhibitors and methods for treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63907A0 (en) 1980-09-24 1981-12-31 Cetus Corp Diagnostic method and antibody probe for use therein
ATE53862T1 (de) 1982-01-22 1990-06-15 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP4965623B2 (ja) 2009-09-30 2012-07-04 インターナショナル・ビジネス・マシーンズ・コーポレーション 所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014022332A1 (en) 2012-07-31 2014-02-06 The Brigham And Women's Hospital, Inc. Modulation of the immune response
US10344088B2 (en) 2013-03-15 2019-07-09 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
WO2015036499A1 (en) 2013-09-11 2015-03-19 Medimmune Limited Anti-b7-h1 antibodies for treating tumors
AU2015225867B2 (en) 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018107173A1 (en) * 2016-12-09 2018-06-14 Vanderbilt University Glutamine transport inhibitors and methods for treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KOSUKE TODA ET AL.,: "Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer", 《INTENATIONAL JOURNAL OF MOLECULAR SCIENCE》, pages 1 - 13 *
MICHAEL L. SCHULTE ET AL.,: "2-amino-4-bis(aryloxybenzyl)aminobutanoic acids: a novel Scaffold for inhibition of ASCT2-mediated glutamine transport", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》,, vol. 26, no. 3, pages 1 - 14 *
MICHAEL L. SCHULTE ET AL.,: "Pharmacological Blockade of ASCT2-dependent Glutamine Transport Leads To Anti-tumor Efficacy in Preclinical Models", 《NATURE MEDICINE》, vol. 24, no. 2, pages 194 - 202 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117466761A (zh) * 2022-07-21 2024-01-30 中国药科大学 谷氨酰胺转运抑制剂、药物组合物和应用
CN117466761B (zh) * 2022-07-21 2026-04-28 中国药科大学 谷氨酰胺转运抑制剂、药物组合物和应用
CN116410152A (zh) * 2023-04-13 2023-07-11 江苏征瑞医药科技有限公司 一种抑制asct2的小分子化合物、其衍生物及其应用
CN116410152B (zh) * 2023-04-13 2023-11-03 江苏征瑞医药科技有限公司 一种抑制asct2的小分子化合物、其衍生物及其应用
CN117550997A (zh) * 2023-11-09 2024-02-13 中国药科大学 一种lat1抑制剂及其制法和应用
CN117550997B (zh) * 2023-11-09 2025-12-19 中国药科大学 一种lat1抑制剂及其制法和应用

Also Published As

Publication number Publication date
CA3141414A1 (en) 2020-12-17
WO2020252336A1 (en) 2020-12-17
EP3983377A1 (en) 2022-04-20
AU2020291936A1 (en) 2022-02-03
US20220265590A1 (en) 2022-08-25
JP2022536728A (ja) 2022-08-18

Similar Documents

Publication Publication Date Title
CN114269715A (zh) 作为氨基酸转运抑制剂的二苄基胺
CN114222729A (zh) 氨基酸转运抑制剂及其用途
KR102491013B1 (ko) Tg02를 사용한 암의 치료
US20220388978A1 (en) Cereblon e3 ligase inhibitors
JP7250764B2 (ja) Ｔｇ０２の多形形態
JP2019511528A (ja) Ｂｅｔタンパク質分解剤
JP7574198B2 (ja) Ｄｏｎプロドラッグおよび免疫チェックポイント阻害剤による組み合わせ治療法
US20240166647A1 (en) Cereblon Ligands
US20240174658A1 (en) Heteroaromatic Inhibitors of Cancer Metabolism
HK40030306A (en) Polymorphic form of tg02
WO2022261117A1 (en) Combination therapy with a don prodrug and a tigit inhibitor
WO2022140661A1 (en) Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor
HK40030306B (zh) Tg02的多晶型形式

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220401

WD01 Invention patent application deemed withdrawn after publication